| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03241810 2017-000565-76 Details | 2020-09-02 Interventional | 2 | 22 | Fulvestrant Breast Neoplasm… Metastatic Brea… | Merrimack Inc. terminated the trial early due to business decision Sponsor (Merrimack Pharmaceuticals, INC.) terminated the trial early due to business decision | |||
| NCT03225924 Details | 2020-09-02 Interventional | 1/2 | 25 | Cyclophosphamid… Doxorubicin Prednisone Rituximab Vincristine DLBCL | Stop of drug development - | |||
| NCT03106571 Details | 2020-09-01 Interventional | 1 | 19 | Methamphetamine Methamphetamine… | Deemed unable to enroll targeted participants in part due to COVID-19 shut downs - | |||
| NCT01731691 Details | 2020-08-31 Interventional | 2/3 | [1 Refs] | 12 | Alpha 1-Antitry… Protease Inhibi… Acquired Immuno… HIV Infections HIV Disease | Blinded review of the data suggested no significant diferences in outcomes. Early termination leading to small numbers of subjects analyzed; Technical problems with measurement leading to unreliable or uninterpretable data. | ||
| NCT04351919 Details | 2020-08-28 Interventional | 4 | 0 | Azithromycin Hydroxychloroqu… COVID-19 Patients With C… | - Interest in the use of HCQ is controversial. - | |||
| NCT04349228 Details | 2020-08-28 Interventional | 3 | 0 | Hydroxychloroqu… COVID-19 COVID19 Healthcare Work… Hydroxychloroqu… Prophylaxis Sars-CoV2 | - Interest in the use of HCQ is controversial. - | |||
| NCT04528927 Details | 2020-08-27 Interventional | 3 | 0 | Azithromycin Doxycycline COVID-19 Respiratory Ins… COVID 19 Patients Hospit… | - Interest in the use of HCQ is controversial. - | |||
| NCT03213626 Details | 2020-08-27 Interventional | 2 | 7 | Erlotinib Hydro… Adenocarcinoma Pancreatic Aden… | There were no objective responses by patient 7. - | |||
| NCT02346955 Details | 2020-08-27 Interventional | 1 | 27 | Pembrolizumab Carcinoma, Non-… Bladder Cancer Colorectal Canc… Gastric Cancer Melanoma Non-small Cell … Ovarian Cancer | - - | |||
| NCT01535157 NCT01550692 Details | 2020-08-27 Interventional | 1/2 | 12 | Fenretinide Ketoconazole Retinamide Carcinoma Carcinoma, Ovar… Ovarian Neoplas… Cancer of Ovary Cancer of the O… Ovarian Cancer Ovary Neoplasms Primary Periton… | drug combination not providing any efficacy. Will use this data in opening new trial - | |||
| NCT04053543 Details | 2020-08-26 Interventional | 2 | 33 | CXA-10 Hypertension Pulmonary Arter… PAH | LOE - | |||
| NCT03351231 2017-003603-21 Details | 2020-08-26 Interventional | 1/2 | 7 | Nivolumab Cancer | Inability to meet protocol objectives - | |||
| NCT03232632 Details | 2020-08-26 Interventional | 1 | 7 | Flutemetamol Amyloidosis Cardiac Amyloid… | intervention programming - | |||
| NCT02971839 Details | 2020-08-26 Interventional | 2 | 11 | Ivacaftor Cystic Fibrosis Fibrosis | Decision by Sponsor. - | |||
| NCT02591199 Details | 2020-08-26 Interventional | 2 | 92 | Heparin Lidocaine Cystitis Cystitis, Inter… Somatoform Diso… Syndrome Bladder Pain Sy… Interstitial Cy… | Prematurely terminated based on interim study analysis - | |||
| NCT02558023 Details | 2020-08-25 Interventional | 3 | 14 | Nicardipine Urapidil Hypertension Pre-Eclampsia Preeclampsia | no candidats - | |||
| NCT00859495 Details | 2020-08-25 Interventional | 2 | 9 | Doxorubicin Pemetrexed Mesothelioma Mesothelioma, M… Pleural Mesothe… | - Study was terminated early due to the retirement of the study physician responsible for the P-32 radiotherapy, and the need for further funding. | |||
| NCT03498196 Details | 2020-08-24 Interventional | 1/2 | 1 | Avelumab Urinary Bladder… Bladder Cancer Invasive Bladde… Metastatic Blad… | The sponsor of this study has terminated the study due to poor enrollment. - | |||
| NCT01038856 Details | 2020-08-24 Interventional | 2 | 5 | Erlotinib Hydro… Polycythemia Polycythemia Ve… | The study was terminated by the sponsor - | |||
| NCT00443963 Details | 2020-08-24 Interventional | 4 | 0 | Esomeprazole Ranitidine Dyspepsia | The study was not approved by the Human Studies Subcommittee. - |